

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner: Camtu T. Nguyen

Yoe et al.

Serial No. 09/872,135

Art Unit: 3743

Filed: May 31, 2001

Title: Radiation or Drug Delivery Source with Activity Gradient to Minimize Edge Effects

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§1.97-1.98**

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. Copies of the cited patents and other non-patent documents have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

09/13/2004 EAREGAY1 00000077 071850 09872135


02 FC:1806 180.00 DA

The present Information Disclosure Statement is being submitted after receiving an Office Action and after three months of the filing date of the above-identified application. Therefore, the fee of \$180.00 as specified in 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) is authorized to be charged to Deposit Account No. 07-1850.

Date: September 10, 2004

SQUIRE, SANDERS & DEMPSEY L.L.P.
One Maritime Plaza, Suite 300
San Francisco, CA 94111
Telephone (415) 954-0200
Facsimile (415) 393-9887

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'P. Meyer', is written over a horizontal line.

Paul J. Meyer, Jr.
Attorney for Applicants
Reg. No. 47,791

FORM PTO-1449 (Modified)

Approved for use through 10/31/2002

US DEPARTMENT OF COMMERCE

US Patent and Trademark Office

Docket No.

50623.168

Application No.

09/872,135

**INFORMATION DISCLOSURE CITATION
in an Application**

(Use several sheets if necessary)

Applicant

Brandon James Yoe et al.

Filing Date

May 31, 2001

Group Art Unit

3743

U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date If Appropriate
	A1	4,733,665 C2	1/29/02	Palmaz (Reexamination Certificate)	606	108	
	A2	5,810,873	9/22/98	Morales	606	198	
	A3	5,871,436	2/16/99	Eury	600	3	
	A4	5,947,993	9/7/99	Morales	606	198	
	A5	6,481,262	11/19/02	Ching et al.	72	416	6/20/01
	A6	6,510,722	1/28/03	Ching et al.	72	402	5/10/00
	A7	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00
	A8	6,596,296	7/22/03	Nelson et al.	424	426	8/4/00
	A9	6,656,216	12/2/03	Hossainy et al.	623	1.13	6/29/01
	A10	6,663,662	12/16/03	Pacetti et al.	623	1.13	12/28/00
	A11	6,699,281	3/2/04	Vallana et al.	623	1.42	7/18/02
	A12	6,764,505	7/20/04	Hossainy et al.	623	1.15	4/12/01
	A13	2002/0183581	12/5/02	Yoe et al.	600	3	5/31/01
	A14	09/894,293		Roorda et al.			6/27/01
	A15	10/177,154		Hossainy et al.			6/21/02
	A16	10/293,658		Santos et al.			11/12/02
	A17	10/835,229		Prabhu et al.			4/28/04

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
	B1							
	B2							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Crowe et al., <i>Absorption and Intestinal Metabolism of SDZ-RAD and Rapamycin in Rats</i> , Drug Metabolism and Disposition, Vol. 27, No. 5, pp. 627-632 (1999).
C2	FFS700 MSI Balloon Form/Fold/Set Equipment (PTCA), FFS800 MSI Balloon Form/Fold/Set Equipment (PTA), Machine Solutions, http://machinesolutions.org/ffs7_8.html , 2 pages, printed 11/21/03.
C3	Fischell et al., <i>The Bx VELOCITY™ STENT</i> (Biocompatibles Ltd.), 5 pages (2001).
C4	Gercken et al., <i>Results of the Jostent Coronary Stent Graft Implantation in Various Clinical Settings: Procedural and Follow-Up Results</i> , Vol. 56, No. 3, pp. 353-360 (2002).

C5	GUIDANT MULTI-LINK VISION OTW Coronary Stent System, 2 pages.
C6	Kawai et al., <i>Physiologically Based Pharmacokinetics of Cyclosporine A: Extension to Tissue Distribution Kinetics in Rats and Scale-up to Human</i> , The Journal of Pharmacology and Experimental Therapeutics, Vol. 287, No. 2, pp. 457-468 (1998).
C7	Kovarik et al., <i>Pharmacokinetic and Pharmacodynamic Assessments of HMG-CoA Reductase Inhibitors When Coadministered with Everolimus</i> , Journal of Clinical Pharmacology, Vol. 42, pp. 222-228 (2002).
C8	Lemos et al., <i>Coronary Restenosis After Sirolimus-Eluting Stent Implantation</i> , Circulation, Vol. 108, No. 3, pp. 257-260 (July 22, 2003).
C9	SC700 MSI Stent Crimping Equipment (PTCA), SC800 MSI Stent Crimping Equipment (PTA), Machine Solutions, http://www.machinesolutions.org/sc7_8.html , 2 pages, printed 11/21/03.
C10	Serkova et al., <i>Tissue Distribution and Clinical Monitoring of the Novel Macrolide Immunosuppressant SDZ-RAD and its Metabolites in Monkey Lung Transplant Recipients: Interaction with Cyclosporine</i> , The Journal of Pharmacology and Experimental Therapeutics, Vol. 294, No. 1, pp. 323-332 (2000).
C11	Zimarino et al., <i>Analysis of Stent Edge Restenosis with Different Forms of Brachytherapy</i> , The American Journal of Cardiology, Vol. 89, pp. 322-325 (February 1, 2002).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant.